APELLIS PHARMACEUTICALS, INC.

(APLS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer CEO says Omicron-targeted vaccine is most likely outcome

01/10/2022 | 07:39am EDT

Jan 10 (Reuters) - Pfizer Inc Chief Executive Albert Bourla on Monday said a redesigned COVID-19 vaccine that specifically targets the Omicron coronavirus variant is likely needed and his company could have one ready to launch by March.

Bourla said Pfizer and partner BioNTech SE are working on both an Omicron-targeted vaccine version as well as a shot that would include both the previous vaccine as well as one targeted at the fast-spreading variant.

"I think it is the most likely scenario," Bourla said, speaking at J.P. Morgan's annual healthcare conference, which is being held virtually this year. "We're working on higher doses. We're working different schedules. We're doing a lot of things right now, as we speak."

Bourla said Pfizer could be ready to file for U.S. regulatory approval for a redesigned vaccine and launch it as soon as March. Bourla said Pfizer has built up so much manufacturing capacity for the vaccine that it will not be a problem to switch immediately.

COVID-19 vaccines eventually could be an annual shot for most people, Bourla said, and some high-risk groups might be eligible to receive the shots more often than that.

Moderna Inc CEO Stephane Bancel said last week that people could need another shot this fall, as the efficacy of boosters is likely to decline over the next few months.

An Omicron-driven spike in COVID-19 cases has forced some nations to look to another booster dose, but early signs suggest repeat vaccination may be a hard sell https://www.reuters.com/business/healthcare-pharmaceuticals/pandemic-fatigue-makes-case-boosters-harder-sell-2022-01-10.

Pfizer earlier in the day announced three deals to broaden the use of the messenger RNA technology (mRNA) that its COVID-19 vaccine was based on, including a pact worth as much as $1.35 billion with gene-editing specialist Beam Therapeutics.

The U.S. drugmaker has been looking to advance the development of mRNA-based vaccines and therapeutics after it led global efforts to develop a COVID-19 shot against the COVID-19 pandemic.

The company will also collaborate with Codex DNA Inc to leverage the biotech's proprietary technology, which could enable more efficient development of mRNA-based vaccines, therapeutics and other biopharma products.

Its deal with private biotech Acuitas Therapeutics will focus on the use of the Vancouver-based company's lipid nanoparticle technology for developing up to 10 vaccines or therapeutics.

(Reporting by Michael Erman in New York, Bhanvi Satija, Manojna Maddipatla and Mrinalika Roy in Bengaluru; Editing by Will Dunham, Devika Syamnath and Aditya Soni)


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
APELLIS PHARMACEUTICALS, INC. -3.88% 40.94 Delayed Quote.-10.00%
BEAM THERAPEUTICS INC. 1.48% 31.92 Delayed Quote.-60.55%
BIONTECH SE 0.01% 154.49 Delayed Quote.-40.07%
CODEX DNA, INC. -7.35% 4.16 Delayed Quote.-58.43%
MODERNA, INC. -1.17% 130.49 Delayed Quote.-48.00%
PFIZER, INC. 0.59% 53.735 Delayed Quote.-9.55%
All news about APELLIS PHARMACEUTICALS, INC.
05/24Goldman Sachs Adjusts Apellis Pharmaceuticals' Price Target to $84 from $94, Keeps Buy ..
MT
05/20Credit Suisse Raises Apellis Pharmaceuticals' Price Target to $49 from $44, Maintains N..
MT
05/12Apellis Announces Seven Abstracts in PNH to be Presented at the European Hematology Ass..
GL
05/12Apellis Announces Seven Abstracts in PNH to be Presented at the European Hematology Ass..
AQ
05/11TRANSCRIPT : Apellis Pharmaceuticals, Inc. Presents at Bank of America 2022 Healthcare Con..
CI
05/09Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
05/06Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4..
GL
05/06Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4..
AQ
05/05Apellis Pharmaceuticals to Present at the Bank of America Securities 2022 Healthcare Co..
GL
05/05Raymond James Adjusts Apellis Pharmaceuticals' Price Target to $102 from $114, Keeps St..
MT
More news
Analyst Recommendations on APELLIS PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 92,9 M - -
Net income 2022 -579 M - -
Net cash 2022 420 M - -
P/E ratio 2022 -7,63x
Yield 2022 -
Capitalization 4 533 M 4 533 M -
EV / Sales 2022 44,3x
EV / Sales 2023 15,1x
Nbr of Employees 476
Free-Float 83,0%
Chart APELLIS PHARMACEUTICALS, INC.
Duration : Period :
Apellis Pharmaceuticals, Inc. Technical Analysis Chart | APLS | US03753U1060 | MarketScreener
Technical analysis trends APELLIS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Last Close Price 42,55 $
Average target price 71,73 $
Spread / Average Target 68,6%
EPS Revisions
Managers and Directors
Cedric Francois President, Chief Executive Officer & Director
Timothy Eugene Sullivan Chief Financial Officer & Treasurer
Lok Chung Chan Chairman
Pascal Deschatelets Chief Scientific Officer
Federico Grossi Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
APELLIS PHARMACEUTICALS, INC.-10.00%4 533
CSL LIMITED-5.70%93 360
SAMSUNG BIOLOGICS CO.,LTD.-7.97%45 499
BIOGEN INC.-15.58%29 662
WUXI BIOLOGICS (CAYMAN) INC.-42.63%28 538
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-28.05%21 450